Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings secures medical cannabis funding

The placement welcomes a top tier Australian fund to the register.
AusCann Group Holdings secures medical cannabis funding
AusCann has raised funds

AusCann Group Holdings (ASX:AC8) has raised $12 million through the placement of 24 million shares priced at $0.50 to institutional and high net worth investors.

Significantly, the placement price is more than double the price of the company’s ASX debut in February of $0.20.

This demonstrates the high market demand for the company and validates AusCann’s strategy as an Australian-based and globally connected player in the medicinal cannabis sector.

Canopy Growth Corporation, North America’s leading cannabis producer and AusCann’s strategic partner, participated in this placement.

Canopy’s investment was complemented by strong interest from a range of other institutional investors including leading Australian fund manager Tribeca Investment Partners.

Elaine Darby, managing director, commented: “The strong support we have received for this capital raising continues to demonstrate the high level of investor interest in the medicinal cannabis sector in Australia.”


Recent partnership with Tasmanian Alkaloids

Earlier this week, AusCann signed a heads of agreement to form a long-term exclusive strategic partnership with Tasmanian Alkaloids, a global poppy grower and processor.

The two companies will work together to establish cultivation, manufacturing and distribution operations for medicinal cannabis in Australia and overseas.

Jointly, the two companies will secure a licence to cultivate and manufacture medicinal cannabis in Tasmania.

The Tasmanian license will be in addition to AusCann’s current medical cannabis cultivation licence granted last week by the Office of Drug Control.

Tasmanian Alkaloids is an established manufacturer of alkaloid raw materials and produces circa 40% of the world’s alkaloid raw material crop in Tasmania.

It boasts a modern manufacturing facility, which is fully compliant with Good Manufacturing Practice standards.

Tasmanian Alkaloids has established relationships with many of the world’s leading pharmaceutical companies and is the largest producer and exporter of thebaine, and also produces oripavine and codeine at its Tasmanian facility.

AusCann and Tasmanian Alkaloids will work together to establish cultivation, manufacturing and distribution operations for medicinal cannabis in Australia and overseas.


Background

AusCann is a medical cannabis company that commenced trading on the ASX in February after it raised the maximum $5 million under a prospectus offering.

The company aims to produce and provide high quality, affordable and clinically validated cannabis medicines to patients.

It is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, from cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners across the globe.

Partners include:

- Canopy Growth Corp (CVE:CGC): the largest producer of medicinal cannabis globally;
- DayaCann: the only licensed medicinal cannabis grower in Chile; and
- Tasmanian Alkaloids: producer of ~40% of the world’s alkaloid raw material.

During early May, AusCann was granted a licence to cultivate medicinal cannabis in Australia.

The global cannabis market is currently valued at US$50 billion and growing, with an estimated 600,000 patients currently receiving treatment.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use